Intellia Therapeutics

Yahoo Finance • 3 days ago

Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight

The hereditary transthyretin amyloidosis market is experiencing significant growth driven by increasing disease awareness, advancements in gene-silencing therapies, and the rising prevalence of the condition globally. The market is further... Full story

Yahoo Finance • 5 days ago

Stocks Settle Mostly Higher as AI Frenzy Boosts Chipmakers

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.36%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.78%.  December E-mini S&P futures (ESZ25) rose +0.37%, and Dec... Full story

Yahoo Finance • 5 days ago

Stocks Gain on Strength in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is up +0.20%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.59%.  December E-mini S&P futures (ESZ25) are up +0.21%, and December E-mini N... Full story

Yahoo Finance • 5 days ago

Stocks making the biggest moves midday: Critical Metals, Comerica, Advanced Micro Devices, Abercrombie & Fitch and more

Check out the companies making the biggest moves midday: Verizon Communications — The New York-based telecom provider sank nearly 4% after CEO Hans Vestberg stepped down , replaced by independent lead director and former PayPal CEO Dan Sch... Full story

Yahoo Finance • 5 days ago

Stocks Supported by AI Spending

The S&P 500 Index ($SPX) (SPY) today is up +0.20%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.60%.  December E-mini S&P futures (ESZ25) are up +0.21%, and December E-mini N... Full story

Yahoo Finance • 5 days ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 8 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October... Full story

Yahoo Finance • 12 days ago

Cathie Wood makes surprising deeper bet on robotaxis

Cathie Wood has built ARK Invest around the idea that disruptive autonomy changes the game completely. She’s been bullish on robotaxis for years, arguing that it’s likely to flip auto economics into software-like margins and dominate valu... Full story

Yahoo Finance • 12 days ago

Cathie Wood's Ark Invest weekly recap: adds Chinese tech names, Intellia Therapeutics

ARK Invest CEO Cathie Wood recently pointed out that the AI space is ruled by “big four” players: OpenAI, Anthropic, Elon Musk’s xAI, and Google’s (GOOG [https://seekingalpha.com/symbol/GOOG]) Gemini, describing the competition among these... Full story

Yahoo Finance • 16 days ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinu... Full story

Yahoo Finance • 19 days ago

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-te... Full story

Yahoo Finance • 23 days ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Completed patient enrollment within nine months with nearly half enrolled from the U.S.Expect to report Phase 3 topline data in the first half of 2026On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the f... Full story

Yahoo Finance • last month

Cathie Wood’s Ark Invest buys the dip in Figma as stock sinks ~20%

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s investment manager Ark Invest has bought over 100K shares of Figma (NYSE:FIG [https://seekingalpha.co... Full story

Yahoo Finance • last month

Tesla's India Dream Hits a Wall: Just 600 Orders, While BYD Doubles Down

This article first appeared on GuruFocus. Tesla (NASDAQ:TSLA) may have entered India with brand swagger and long-term ambition, but the initial numbers tell a more muted story. Since launching sales in mid-July, the company has received j... Full story

Yahoo Finance • 2 months ago

Cathie Wood's ARK buys CRISPR, sells Roku and DraftKings stock

Cathie Wood’s ARK ETFs have reported their daily trades for Tuesday, August 26th, 2025, with significant activity in biotech and tech stocks. The largest trade of the day was the purchase of 165,874 shares of CRISPR THERAPEUTICS AG (NASDAQ... Full story

Yahoo Finance • 2 months ago

Cathie Wood's ARK shifts focus, buys CRSP stock, sells ROKU

Cathie Wood’s ARK ETF released their daily trades for Monday, August 25th, 2025, revealing a significant reshuffle in their portfolio. The firm’s largest transaction involved selling 141,194 shares of Roku Inc (NASDAQ:ROKU), amounting to a... Full story

Yahoo Finance • 2 months ago

Monday 8/25 Insider Buying Report: NTLA, INR

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is... Full story

Yahoo Finance • 2 months ago

Cathie Wood's ARK ETF adjusts portfolio with PagerDuty and Robinhood stock trades

Cathie Wood’s ARK ETFs have published their daily trades for Thursday, 21 August 2025, unveiling a series of strategic buy and sell moves in the tech and biotech sectors. The most significant transaction of the day was the purchase of 138,... Full story

Yahoo Finance • 2 months ago

Attack Surface Management Market Surges to $3.3 billion by 2029 - Dominated by Palo Alto Networks (US), IBM(US), Microsoft (US)

Delray Beach, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the Attack Surface Management Market estimated value stands at USD 0.9 billion in 2024, with projections indicating it could soar to USD 3.3 billion by... Full story

Yahoo Finance • 2 months ago

ARK Investment buys 560K shares of Intellia Therapeutics

* Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]). * The stock has a Seeking Alpha quant rating of Hold, [https://... Full story